Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy

By Davis Keith L.   Tangirala Muralikrishna   Meyers Juliana L.   Wei Wenhui  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1083-1091

Informa Healthcare

Access to resources Recommend Favorite

Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients

By Suh Dong-Churl   Lee Dong-Hyun   McGuire Michael   Kim Chul-Min  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1623-1633

Informa Healthcare

Access to resources Recommend Favorite

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies

By Xie Lin   Wei Wenhui   Pan Chunshen   Baser Onur  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1137-1145

Informa Healthcare

Access to resources Recommend Favorite